Otlertuzumab
Otlertuzumab
Otlertuzumab (pronunciation: ot-ler-tuz-u-mab) is a monoclonal antibody designed for the treatment of cancer. It is a biopharmaceutical product that is still in the experimental stages of development.
Etymology
The name "Otlertuzumab" follows the World Health Organization's guidelines for the International Nonproprietary Names (INN) of monoclonal antibodies. The "-mab" suffix indicates it is a monoclonal antibody, while the "tuzu-" stem suggests it is a humanized antibody. The prefix "Otl-" does not have a specific meaning and is randomly assigned.
Mechanism of Action
Otlertuzumab works by targeting the CD37 antigen, a protein found on the surface of B cells. By binding to this antigen, it can induce apoptosis, or programmed cell death, in the cancerous cells.
Clinical Trials
Otlertuzumab has been tested in several clinical trials for various types of cancer, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). However, it is not yet approved for use by any health regulatory authority.
Related Terms
- Monoclonal antibody
- Biopharmaceutical
- CD37 antigen
- B cells
- Apoptosis
- Clinical trials
- Chronic lymphocytic leukemia
- Non-Hodgkin lymphoma
External links
- Medical encyclopedia article on Otlertuzumab
- Wikipedia's article - Otlertuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski